Skip to main content
SpringerLink
Log in

Evaluation of guideline-based cardiovascular medications and their respective doses in heart failure patients in Oman

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Significant gaps exist between guidelines and practice in the management of heart failure, not only in Oman but the Arabian Gulf region in general. Currently, only limited research exists on the use of these guideline-based cardiovascular medications and their corresponding target doses in the region. Objective To evaluate the use of guideline-based cardiovascular medications and their corresponding target doses in heart failure patients with reduced (< 40%) and mid-range (40–49%) ejection fraction in Oman. Setting Cardiology clinics at Sultan Qaboos University Hospital, Muscat, Oman. Methods The study included heart failure patients seen at the clinics between January 2016 and December 2019. The use of angiotensin-converting-enzyme inhibitors (captopril, lisinopril) or angiotensin II receptor blockers (irbesartan, valsartan), β-blockers (bisoprolol, carvedilol) and spironolactone along with their respective target doses were evaluated as per the European, American, and Canadian heart failure guidelines. Analyses were performed using univariate statistics. Main outcome measure The proportion of patients that was prescribed guideline-based heart failure medications along with their target doses as per guidelines. Results The overall mean age of the cohort (N = 249) was 63 ± 15 years and 61% (n = 151) were males. Seventy-one percent (n = 177) of the patients had heart failure with reduced ejection fraction while 29% (n = 72) had heart failure with mid-range ejection fraction. A total of 87% (n = 216), 62% (n = 154) and 39% (n = 96) of the patients were on β-blockers, angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers and spironolactone, respectively. Only 33% (n = 81) of the patients were on the triple guideline-based cardiovascular medication classes concurrently. Patients with reduced ejection fraction were more likely to be prescribed the triple guideline-based cardiovascular medication classes concurrently than those that had heart failure with mid-range ejection fraction (37% vs 22%; p = 0.027). A total of 100% (96/96), 56% (121/216) and 42% (64/153) of the patients were prescribed ≥ 50% of target dose for spironolactone, β-blockers and angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers, respectively. Conclusions The use of guideline-based cardiovascular medications in heart failure patients with reduced and mid-range ejection fraction is low in Oman. They were also largely not optimally dosed at target levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123–33.

    Article  Google Scholar 

  2. Farré N, Vela E, Clèries M, Bustins M, Cainzos-Achirica M, Enjuanes C, et al. Medical resource use and expenditure in patients with chronic heart failure: a population-based analysis of 88 195 patients. Eur J Heart Fail. 2016;18:1132–40.

    Article  Google Scholar 

  3. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.

    Article  Google Scholar 

  4. Yancy CW, Januzzi JL Jr, Allen LA, Butler J, Davis LL, Fonarow GC, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2018;71:201–30.

    Article  Google Scholar 

  5. Ezekowitz JA, O’Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive update of the Canadian cardiovascular society guide-lines for the management of heart failure. Can J Cardiol. 2017;33:1342–433.

    Article  Google Scholar 

  6. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–92.

    Article  CAS  Google Scholar 

  7. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455–62.

    Article  CAS  Google Scholar 

  8. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81.

    Article  CAS  Google Scholar 

  9. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19:1624–34.

    Article  Google Scholar 

  10. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail. 2017;19:1258–69.

    Article  Google Scholar 

  11. Chang HY, Wang CC, Wei J, Chang CY, Chuang YC, Huang CL, et al. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: results from TSOC-HFrEF registry. J Chin Med Assoc. 2017;80:750–7.

    Article  Google Scholar 

  12. Zubaid M, Rashed W, Ridha M, Bazargani N, Hamad A, Banna RA, et al. Implementation of guideline-recommended therapies for patients with heart failure and reduced ejection fraction: a regional Arab middle east experience. Angiology. 2020;71:431–7.

    Article  Google Scholar 

  13. Krantz MJ, Ambardekar AV, Kaltenbach L, Hernandez AF, Heidenreich PA, Fonarow GC. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from get with the guidelines-heart failure). Am J Cardiol. 2011;107:1818–23.

    Article  Google Scholar 

  14. Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European society of cardiology guidelines? Evidence from 12,440 patients of the ESC heart failure long-term registry. Eur J Heart Fail. 2013;15:1173–84.

    Article  CAS  Google Scholar 

  15. Gjesing A, Schou M, Torp-Pedersen C, Dahlström U, Filippatos G, Ponikowski P, et al. Patient adherence to evidence-based pharmacotherapy in systolic heart failure and the transition of follow-up from specialized heart failure outpatient clinics to primary care. Eur J Heart Fail. 2013;15:671–8.

    Article  CAS  Google Scholar 

  16. Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, et al. Physicians’ adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18:514–22.

    Article  CAS  Google Scholar 

  17. Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351–66.

    Article  Google Scholar 

  18. Diamant MJ, Virani SA, MacKenzie WJ, Ignaszewski A, Toma M, Hawkins NM. Medical therapy doses at hospital discharge in patients with existing and de novo heart failure. ESC Heart Fail. 2019;6:774–83.

    Article  Google Scholar 

  19. Balakumaran K, Patil A, Marsh S, Ingrassia J, Kuo CL, Jacoby DL, et al. Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction. Int J Cardiol Heart Vasc. 2018;22:1–5.

    PubMed  PubMed Central  Google Scholar 

  20. Brunner-La HPR, Linssen GC, Smeele FJ, Ingrassia J, Kuo CL, Jacoby DL, et al. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry. JACC Heart Fail. 2019;7:13–21.

    Article  Google Scholar 

  21. Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018;6:e1008–18.

    Article  Google Scholar 

  22. Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38:1883–90.

    Article  CAS  Google Scholar 

  23. DeVore AD, Thomas L, Albert NM, Butler J, Hernandez AF, Paterson JH, et al. Change the management of patients with heart failure: rationale and design of the CHAMP-HF registry. Am Heart J. 2017;189:177–83.

    Article  Google Scholar 

  24. Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, et al. Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: in-sights from get with the guidelines-heart failure (GWTG-HF). JACC Heart Fail. 2017;5:305–9.

    Article  Google Scholar 

  25. Peterson PN, Rumsfeld JS, Liang L, Hernandez AF, Peterson ED, Fonarow GC, et al. Treatment and risk in heart failure: gaps in evidence or quality? Circ Cardiovasc Qual Outcomes. 2010;3:309–15.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the academic staff (Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman), clinical pharmacists (Department of Pharmacy, Sultan Qaboos Hospital, Muscat, Oman) as well as clinical physiology technologists (Department of Clinical Physiology, Sultan Qaboos Hospital, Muscat, Oman), for their kind contribution in logistically helping with the data capture from the Hospital Information System as well as reviewing the study findings.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, PO Box 38, Al-Khodh, PC-123, Muscat, Sultanate of Oman

    Diana Arandi Hanbali, Mohammed Al Za’abi & Ibrahim Al-Zakwani

  2. Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Sultanate of Oman

    Khamis Al Hashmi

  3. Gulf Health Research, Muscat, Sultanate of Oman

    Ibrahim Al-Zakwani

Authors
  1. Diana Arandi Hanbali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Khamis Al Hashmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammed Al Za’abi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ibrahim Al-Zakwani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ibrahim Al-Zakwani.

Ethics declarations

Funding

This study was a thesis project for an M.Sc student (Diana Arandi Hanbali, first author) and was not funded.

Conflicts of interest

The authors declare no conflicts of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hanbali, D.A., Hashmi, K.A., Za’abi, M.A. et al. Evaluation of guideline-based cardiovascular medications and their respective doses in heart failure patients in Oman. Int J Clin Pharm 43, 878–883 (2021). https://doi.org/10.1007/s11096-020-01190-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-020-01190-2

Keywords

Search

Navigation